Patents by Inventor Kan He
Kan He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180099961Abstract: The present invention concerns novel deuterated and non-deuterated cyclic chemical compounds and their corresponding salts thereof active on protein kinases in general, and in particular as inhibitors of protein kinases. Additionally, methods of treating mammals with protein kinase-mediated diseases or conditions by administering a therapeutically effective amount of the novel deuterated or non-deuterated cyclic chemical compound and their corresponding salts thereof.Type: ApplicationFiled: December 12, 2017Publication date: April 12, 2018Applicant: Princeton Drug Discovery IncInventor: Kan He
-
Patent number: 9890163Abstract: Protein kinases are regulators of cellular signaling and their functional dysregulation is common in carcinogenesis and many other disease states or disorders. The present invention relates to novel chemical entities that have biological activity to modulate mammalian protein kinase enzymes. In particular, compounds of the invention display potent inhibition of breast tumor related kinase (BRK).Type: GrantFiled: October 11, 2016Date of Patent: February 13, 2018Assignee: Princeton Drug Discovery IncInventors: Kan He, Lining Cai
-
Publication number: 20170343535Abstract: A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.Type: ApplicationFiled: August 11, 2017Publication date: November 30, 2017Applicant: Biotranex, LLCInventor: Kan He
-
Publication number: 20170275589Abstract: A method is provided to measure modulation of phosphatidylcholine export transport and/or formation activity in hepatocyte or stable cell-line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, amino acids, peptides, proteins, oligonucleotides, DNA, and RNA. Furthermore, the method is designed to determine modulation of phosphatidylcholine transport and/or formation activity not only by said test agents, but also their metabolites or biotransformation products formed in situ.Type: ApplicationFiled: March 29, 2016Publication date: September 28, 2017Applicant: Biotranex, LLCInventor: Kan He
-
Patent number: 9772325Abstract: A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or bio transformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.Type: GrantFiled: June 5, 2014Date of Patent: September 26, 2017Assignee: Biotranex, LLCInventor: Kan He
-
Publication number: 20170240545Abstract: Protein kinases are regulators of cellular signaling and their functional dysregulation is common in carcinogenesis and many other disease states or disorders. The present invention relates to novel chemical entities that have biological activity to modulate mammalian protein kinase enzymes. In particular, compounds of the invention display potent inhibition of breast tumor related kinase (BRK).Type: ApplicationFiled: October 11, 2016Publication date: August 24, 2017Applicant: Princeton Drug Discovery, LLCInventors: Kan He, Lining Cai
-
Publication number: 20160054305Abstract: A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.Type: ApplicationFiled: June 5, 2014Publication date: February 25, 2016Applicant: BIOTRANEX, LLCInventor: Kan He
-
Publication number: 20150306119Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total ginsenosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: ApplicationFiled: February 27, 2015Publication date: October 29, 2015Applicant: NATUREX, S.A.Inventors: Andrew SCHOLEY, Alvin IBARRA, Kan HE, Marc ROLLER, Jacques DIKANSKY
-
Patent number: 9090568Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.Type: GrantFiled: March 12, 2012Date of Patent: July 28, 2015Assignee: IMPACT Therapeutics, Inc.Inventors: Dong Liu, Minsheng Zhang, Kan He, Lianshan Zhang
-
Patent number: 9011936Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.Type: GrantFiled: October 16, 2009Date of Patent: April 21, 2015Assignee: Naturex, S.A.Inventors: Kan He, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques DiKansky
-
Patent number: 8968800Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: GrantFiled: November 3, 2011Date of Patent: March 3, 2015Assignee: Naturex, S.A.Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
-
Patent number: 8951993Abstract: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.Type: GrantFiled: February 22, 2012Date of Patent: February 10, 2015Assignee: Jiangsu Hansoh Pharmaceutical Co., Ltd.Inventors: Baihua Hu, Kan He, Minsheng Zhang
-
Publication number: 20140031358Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.Type: ApplicationFiled: March 12, 2012Publication date: January 30, 2014Applicant: Eternity Bioscience Inc.Inventors: Dong Liu, Minsheng Zhang, Kan He, Lianshan Zhang
-
Patent number: 8477151Abstract: Methods and systems for boundary delineation are described. In one embodiment, a living unit identifier may be translated into a translated geographic location point. The living unit identifier may be within a distribution area. A closed plane living unit-based figure that bounds the translated geographic location point may be delineated. An additional closed plane living unit-based figure that bounds a geographic location point may be delineated. The geographic location point may be associated with an additional living unit identifier within the distribution area. The closed plane living unit-based figure and the additional closed plane living unit-based figure may be merged to create a distribution area figure of the distribution area. Additional methods and systems are disclosed.Type: GrantFiled: November 18, 2008Date of Patent: July 2, 2013Assignee: AT&T Intellectual Property I, L.P.Inventor: Kan He
-
Patent number: 8293292Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S)2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.Type: GrantFiled: November 10, 2011Date of Patent: October 23, 2012Assignee: Naturex, S.A.Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques DiKansky, Alvin Ibarra
-
Publication number: 20120220551Abstract: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.Type: ApplicationFiled: February 22, 2012Publication date: August 30, 2012Applicant: Eternity Bioscience Inc.Inventors: Baihua Hu, Kan He, Minsheng Zhang
-
Patent number: 8142826Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.Type: GrantFiled: August 4, 2008Date of Patent: March 27, 2012Assignee: Naturex, Inc.Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques Dikansky, Alvin Ibarra
-
Publication number: 20120058210Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.Type: ApplicationFiled: November 10, 2011Publication date: March 8, 2012Inventors: KAN HE, Marc ROLLER, Antoine BILY, Naisheng BAI, Jacques DIKANSKY, Alvin IBARRA
-
Publication number: 20120046239Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.Type: ApplicationFiled: November 3, 2011Publication date: February 23, 2012Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
-
Patent number: RE43005Abstract: The invention relates to compositions that can be isolated from Lepidium plant material and to methods for their isolation. The compositions are useful for treating and preventing cancer and sexual dysfunction.Type: GrantFiled: November 21, 2007Date of Patent: December 6, 2011Assignee: Naturex Inc.Inventors: Bo Lin Zheng, Kan He, Yu Shao, Qun Yi Zheng